Regeneron Pharmaceuticals Inc. buy Rothschild & Co Redburn
Start price
14.08.25
/
50%
€481.00
Target price
14.08.26
€759.88
Performance (%)
27.16%
Price
20:55
€608.00
Summary
This prediction is currently active. The prediction currently has a performance of 27.16%. A total of €3.64 was paid as dividends for this prediction. This prediction currently runs until 14.08.26. The prediction end date can be changed by Rothschild___Co_Redb at any time. Rothschild___Co_Redb has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regeneron Pharmaceuticals Inc. | 3.107% | 3.107% |
| iShares Core DAX® | 1.717% | 3.368% |
| iShares Nasdaq 100 | -4.565% | -4.238% |
| iShares Nikkei 225® | -7.120% | -11.869% |
| iShares S&P 500 | -0.894% | 1.687% |
Comments by Rothschild___Co_Redb for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Rothschild & Co Redburn. They set a "buy" rating and a $890.00 price target on the stock.
Ratings data for REGN provided by MarketBeat